ERIC JONASCH to Drug Resistance, Neoplasm
This is a "connection" page, showing publications ERIC JONASCH has written about Drug Resistance, Neoplasm.
Connection Strength
0.393
-
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
Score: 0.197
-
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 12; 17(6):451-456.
Score: 0.066
-
Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. Mol Cancer Res. 2019 05; 17(5):1220-1232.
Score: 0.064
-
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
Score: 0.050
-
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
Score: 0.017